- Microbiome-based therapeutics, focusing on modulating the human microbiome to treat or prevent diseases, are becoming increasingly vital in modern healthcare due to a deeper understanding of the microbiome's role in health and disease, alongside advancements in biotechnology
- The escalating demand for these therapeutics is primarily fueled by the rising prevalence of chronic diseases linked to microbiome dysbiosis, such as inflammatory bowel disease (IBD) and Clostridium difficile infection (CDI), and the growing need for novel and effective treatment options beyond traditional therapies
- North America dominates the microbiome-based therapeutics market with the largest revenue share of 76.3% in 2025, characterized by established research infrastructure, significant R&D investments, and a strong presence of key industry players, particularly in the U.S., which benefits from a robust biotechnology sector and supportive regulatory environment driving rapid development and commercialization
- Asia-Pacific is expected to be the fastest growing region in the microbiome-based therapeutics market with a CAGR of 24.5%, during the forecast period due to increasing healthcare spending, rising awareness about gut health, growing research activities, and government support for personalized medicine in countries
- Fecal microbiota therapy segment is expected to dominate the microbiome-based therapeutics market with a market share of 92.1% in 2025, driven by its established efficacy, particularly in treating recurrent Clostridium difficile infection (CDI), and its increasing application in other gastrointestinal disorders
